HB Wealth Management LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

HB Wealth Management LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 43,783 shares of the company's stock after purchasing an additional 1,214 shares during the quarter. HB Wealth Management LLC's holdings in Eli Lilly and Company were worth $33,802,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. KRS Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 3.3% in the fourth quarter. KRS Capital Management LLC now owns 4,906 shares of the company's stock worth $3,788,000 after buying an additional 156 shares during the last quarter. Trust Co. of Vermont raised its position in Eli Lilly and Company by 6.7% in the fourth quarter. Trust Co. of Vermont now owns 8,659 shares of the company's stock worth $6,685,000 after acquiring an additional 542 shares during the period. Shelton Wealth Management LLC raised its position in Eli Lilly and Company by 57.6% in the fourth quarter. Shelton Wealth Management LLC now owns 1,155 shares of the company's stock worth $892,000 after acquiring an additional 422 shares during the period. CGN Advisors LLC boosted its stake in shares of Eli Lilly and Company by 32.9% during the 4th quarter. CGN Advisors LLC now owns 4,199 shares of the company's stock worth $3,242,000 after acquiring an additional 1,040 shares during the last quarter. Finally, Sanibel Captiva Trust Company Inc. grew its position in shares of Eli Lilly and Company by 20.2% during the 4th quarter. Sanibel Captiva Trust Company Inc. now owns 24,165 shares of the company's stock valued at $18,655,000 after acquiring an additional 4,065 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $31.36 during mid-day trading on Monday, reaching $726.24. The stock had a trading volume of 5,497,108 shares, compared to its average volume of 2,736,766. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 1-year low of $612.70 and a 1-year high of $972.53. The firm has a market cap of $689.43 billion, a price-to-earnings ratio of 78.51, a PEG ratio of 1.66 and a beta of 0.41. The business's fifty day moving average is $781.14 and its 200-day moving average is $854.04.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion for the quarter, compared to analysts' expectations of $12.09 billion. During the same period in the prior year, the business posted $0.10 earnings per share. The business's quarterly revenue was up 20.4% compared to the same quarter last year. On average, research analysts forecast that Eli Lilly and Company will post 13.14 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a $1.50 dividend. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.83%. Eli Lilly and Company's dividend payout ratio is presently 56.22%.

Eli Lilly and Company announced that its Board of Directors has authorized a share buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on LLY shares. Truist Financial raised their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a "buy" rating in a research note on Thursday, October 10th. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They set an "outperform" rating and a $1,100.00 price target on the stock. Citigroup increased their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Friday, October 25th. Barclays lowered their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating for the company in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,002.22.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the business's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.